DIL Limited subsidiary, Fermenta Biotech Limited wins accolades at UBM India Pharma Awards 2018


By Vivek K. Mobile: 09920183006 Email:indianshowbusiness@gmail.com

DIL Ltd. (BSE: DIL: 506414) today announced that its subsidiary, Fermenta Biotech Ltd. (FBL) was recognized for excellence at the UBM India Pharma Awards 2018. FBL won three awards including Awards for Excellence in Export Promotion, Pharma International Excellence and Excellence in Corporate Social Responsibility. The prestigious awards were conferred on FBL at a grand event in Delhi attended by pharma industry leaders and visionaries from across the world.

Mr. Prashant Nagre, CEO, Fermenta Biotech Ltd. said, “These awards are testament to our efforts to remain ahead of the curve in a competitive global environment. We are happy to be recognized for our excellence amongst our peers. The award for our CSR efforts is a result of our belief that we should always give back to the community we are present in, and we are happy that our small contribution has been recognized.”

The Excellence in Export Promotion Award was given to FBL for its steady growth in exports over the years with an over 100% growth in FY18 over the previous year. A growth in export customers from 106 in FY15 to 171 in FY18 is a demonstration of its increasing global footprint across 50+ countries over six continents. The world class manufacturing facilities of FBL are cleared by most of the global regulatory agencies including US-FDA and WHO-GMP, and FBL has today established India as a credible alternative to China in the vitamin segment.

The Pharma International Excellence Award honored FBL for achieving success in international markets through world class strategy and operations. From re-engineering business processes through implementation of SAP and CRM initiative like salesforce.com to embracing best in class practices for value enhancement across verticals, FBL is focused on a robust and sustainable future. FBL is innovating in R&D through disruptive technologies such as microencapsulation for increased stability, bioavailability and dosage conformity, and using unconventional methods for revolutionizing enzymes and vitamin manufacturing.

The Excellence in Corporate Social Responsibility Award for companies with turnover < Rs.500 crore, was awarded to FBL for its work in empowering local communities to create sustainable growth. FBL’s internal events are integrated with its social partners to instill a sense of awareness in the culture and engage employees with its CSR activities. Partnering with organizations like the National Association for the Blind to empower people with vision loss through braille kits, squint correction and corneal transplant surgeries, implementing e-learning initiatives in schools in Dahej and Kulu, promoting education for special and differently abled children, and contributing towards rural development through various initiatives, FBL has been increasing its CSR spend over the years. Moving beyond CSR, FBL supports organization like Vitamin Angels, a non-profit organization that provides life changing vitamins to pregnant women, new mothers, and children under five. The award recognizes FBL’s commitment to continue and build upon its good work in future.

Established in 1986, FBL is today the only manufacturer and supplier in India and among the top few manufacturers in the world of Vitamin D3 (Cholecalciferol). FBL pursues Pharmaceuticals, Research and Development and Product delivery across biotechnology and environmental solutions. FBL also pioneered the manufacture of Penicillin G Amidase enzyme in India and today has emerged as the leader in enzyme technologies for beta lactams synthesis. FBL has also commercialized next generation PGA enzyme technologies for Amoxicillin, Ampicillin, Cephalexin and Cefadroxil. DIL holds 91.2% equity stake in FBL.

The UBM India Pharma Awards celebrate excellence and recognize contribution of Indian Pharmaceutical Companies. They provide an opportunity for the companies to showcase their innovations and accomplishments in the sector.

Leave a Reply

Your email address will not be published. Required fields are marked *